Noah Medical’s Galaxy System is used in the US for the first time

Listen to this article

Noah Medical announced that its Galaxy System, an integrated system for navigated robotic bronchoscopy, was used for the first time in the United States at the University of Chicago Medicine by Dr. Kyle Hogarth. 

This procedure marks the first commercial release of the Galaxy System in the US following its recent FDA clearance and first-in-human trials at Macquarie University Hospital in Sydney, Australia. The system was designed to give physicians more confidence in locating and navigating to lung nodules during biopsies as part of a more effective and efficient bronchoscopy procedure. 

 “The Galaxy System is the first robot for peripheral lung navigation that includes integrated imaging, which is the solution bronchoscopists have been asking for,” Hogarth said. “We are excited to be the first hospital in the United States to implement this next-generation robotic solution for our patients which we believe will improve and expedite the early diagnosis and treatment of lung cancer.”

The system uses Noah Medical’s proprietary TiLT+ Technology, which includes integrated tomosynthesis and augmented fluoroscopy, a single-used disposable bronchoscope, and a small, compact footprint. Noah Medical built TiLT+ Technology to overcome CT-to-body divergency by providing real-time navigation and lesion updates with readily available C-arm fluoroscopy. 

During the system’s first-in-human trials, physicians have provided positive feedback on the device’s TiLT+ Technology, its single-use disposable bronchoscope and its small footprint. 

 “Congratulations to Dr. Hogarth and the team at UChicago Medicine for completing this milestone achievement in robotic bronchoscopy,” Jian Zhang, PhD, Noah Medical founder and CEO, said. “We designed the Galaxy System in collaboration with physicians to provide unique clinical value to patients and improved procedural efficiency. We are thrilled to introduce the platform at UChicago Medicine, a pioneer in using life-saving technologies to fight lung cancer.”